Evidence map›Paper›PMID 24739390›Full record

ArticleThe Journal of biological chemistry2014

The transcription factor GLI1 interacts with SMAD proteins to modulate transforming growth factor β-induced gene expression in a p300/CREB-binding protein-associated factor (PCAF)-dependent manner.

Monica D Nye, Luciana L Almada, Maite G Fernandez-Barrena, David L Marks, Sherine F Elsawa, Anne Vrabel, Ezequiel J Tolosa, Volker Ellenrieder, Martin E Fernandez-Zapico

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Interleukin (IL)-7 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021
    Article
  15. GLI1: A Therapeutic Target for Cancer.Frontiers in oncology · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Monica D NyeFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
Luciana L AlmadaFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
Maite G Fernandez-BarrenaFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
David L MarksFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
Sherine F Elsawathe Department of Biological Sciences, Northern Illinois University, De Kalb, Illinois 60115.
Anne VrabelFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
Ezequiel J TolosaFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905.
Volker Ellenriederthe Signaling and Transcription Laboratory, Department of Gastroenterology, Philipps-University of Marburg, 35037 Marburg, Germany, and.
Martin E Fernandez-ZapicoFrom the Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905 fernandezzapico.martin@mayo.edu.
Mayo Clinic · USNovel (United States) · USNorthern Illinois University · USPhilipps University of Marburg · DE

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
TRAINING IN TRANSLATIONAL RESEARCH: BENCH TO BEDSIDER25GM055252 · NIGMS · MAYO CLINIC ROCHESTER · PI LUJAN, LUIS, MAHER, LOUIS JAMES · 1996 to 2022
$8.3M
LINEBERGER CANCER CONTROL EDUCATION PROGRAMR25CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EARP, JO ANNE L, RIBISL, KURT M. · 1992 to 2016
$8.0M
Mechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0M
Role of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI PETERSEN, GLORIA M. · 2003 to 2003
$1.5M
NCI NIH HHS CA136526NCI NIH HHS P20 CA102701NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA136526NCI NIH HHS R25 CA057726NIDDK NIH HHS P30 DK084567NIDDK NIH HHS P30 DK84567NIGMS NIH HHS GM55252NIGMS NIH HHS R25 GM055252
6 · The paper itself

Abstract

The biological role of the transcription factor GLI1 in the regulation of tumor growth is well established; however, the molecular events modulating this phenomenon remain elusive. Here, we demonstrate a novel mechanism underlying the role of GLI1 as an effector of TGFβ signaling in the regulation of gene expression in cancer cells. TGFβ stimulates GLI1 activity in cancer cells and requires its transcriptional activity to induce BCL2 expression. Analysis of the mechanism regulating this interplay identified a new transcriptional complex including GLI1 and the TGFβ-regulated transcription factor, SMAD4. We demonstrate that SMAD4 physically interacts with GLI1 for concerted regulation of gene expression and cellular survival. Activation of the TGFβ pathway induces GLI1-SMAD4 complex binding to the BCL2 promoter whereas disruption of the complex through SMAD4 RNAi depletion impairs GLI1-mediated transcription of BCL2 and cellular survival. Further characterization demonstrated that SMAD2 and the histone acetyltransferase, PCAF, participate in this regulatory mechanism. Both proteins bind to the BCL2 promoter and are required for TGFβ- and GLI1-stimulated gene expression. Moreover, SMAD2/4 RNAi experiments showed that these factors are required for the recruitment of GLI1 to the BCL2 promoter. Finally, we determined whether this novel GLI1 transcriptional pathway could regulate other TGFβ targets. We found that two additional TGFβ-stimulated genes, INTERLEUKIN-7 and CYCLIN D1, are dependent upon the intact GLI1-SMAD-PCAF complex for transcriptional activation. Collectively, these results define a novel epigenetic mechanism that uses the transcription factor GLI1 and its associated complex as a central effector to regulate gene expression in cancer cells.

Indexed as

Carcinoma, Pancreatic DuctalCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansp300-CBP-Associated Factorp300-CBP Transcription FactorsPancreatic NeoplasmsProto-Oncogene Proteins c-bcl-2Signal TransductionSmad2 ProteinSmad3 ProteinSmad4 ProteinTranscription FactorsTransforming Growth Factor beta1Zinc Finger Protein GLI1GLI1 protein, humanp300-CBP-Associated Factorp300-CBP Transcription FactorsProto-Oncogene Proteins c-bcl-2Smad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanSmad4 ProteinSMAD4 protein, humanTranscription FactorsTransforming Growth Factor beta1Zinc Finger Protein GLI1CancerGene ExpressionGLI1PCAFSMAD Transcription FactorTranscription FactorTransforming Growth Factor β (TGFβ)

Identifiers

PMID24739390
PMCPMC4140905
OpenAlexW2007613020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.